Avantor(US:AVTR) Benzingaยท2025-02-07 14:15Core Insights - Avantor Inc reported fourth-quarter net sales of $1.69 billion, a 2% decrease year-over-year, missing the consensus estimate of $1.71 billion [1] - The company experienced a net income increase to $500.4 million from $98.5 million a year ago, with adjusted net income at $183.9 million compared to $166.7 million in the prior period [1][2] - Adjusted EBITDA was reported at $307.7 million with a margin of 18.2%, while adjusted operating income was $279.4 million with a margin of 16.6% [2] - The adjusted EPS was 27 cents, slightly down from 29 cents a year ago, but beating the consensus of 26 cents [2] - Operating cash flow was $173.3 million, and free cash flow was $222.1 million [2] Sales Performance - Laboratory Solutions' net sales were $1.13 billion, down 5%, with a 1% organic sales decline due to foreign currency translation and Clinical Services divestiture [4] - Bioscience Production net sales were $560.8 million, up 4%, with a 4% organic sales increase [4] Future Guidance - Avantor expects organic revenue growth of 1%-3% in 2025 compared to a 2% decline in 2024, with an adjusted EBITDA margin of 18%-19% [4] - The company forecasts adjusted EPS of $1.02-$1.10 versus the consensus of $1.10 and expected free cash flow of $650 million to $700 million [4] Market Reaction - AVTR stock is down 3.73% at $20.89 during the premarket session [5]